oral GPR17 remyelination program
Asset
Antagonism of GPR17 to stimulate oligodendrocyte differentiation and remyelination in multiple sclerosis.
- Stage
- Preclinical
- Modality
- Small molecule
- Target
- GPR17
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Multiple sclerosis
Preclinical, globenewswire.com, 6 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Competitors5
Every asset’s record: target, stage, trials and the evidence behind it.